[Objective]To evaluate the efficacy of Shenmai injection combined with psychotherapy in chemotherapy of non-small cell lung cancer.[Method]79 cases of advanced non-small cell lung cancer were randomly divided into two groups,40 cases in observation group with Shenmai injection combined with chemotherapy and psychotherapy,39 cases in control group with chemotherapy alone.The Karnofsky scores,therapeutic efficacy,one year survival rate and incidence of myelosuppression were evaluated.[Result] The two groups were significantly different in Karnofsky scores,therapeutic efficacy and one year survival rate.The improvement and stability rate of Karnofsky scores and that of therapeutic efficacy were 75.0% and 70.0% in observation group,with 46.2% and 46.2% in control group,respectively.One year survival rate was 47.5% in observation group and 25.6% in control group,respectively.The incidence of myelosuppression had significant differences in the two groups,with grade 2～4 leucopenia 32.5% in observation group and 53.8% in control group(P=0.032),with grade 2～3 thrombocytopenia 30.0% in observation group and 46.2% in control group(P=0.032).[Conclusion] Combination treatment in observation group was superior to the treatment in control group,with a higher Karnofsky scores,more effective therapy,a higher one year survival rate and a lower incidence of myelosuppression.The treatment of Shenmai injection combind with chemotherapy could reduce toxicity and enhance therapeutic efficacy.

Objective To explore the relationship between polymorphism of miR-499A > G with inci-dence and prognosis of colorectal cancer in Han Chinese. Method 1:1 matched case control study was used to collect samples,and the patients were followed up. The genotypes distribution miR-499A > G were detected by TaqMan probe,and logistic regression model and Cox proportional hazard regression model were used to analysis the relationship between miR-499A>G and incidence and prognosis of colorectal cancer. Results 394 cases and 394 controls were recruited,while miR-499A>G did not increase the risk of colorectal cancer(OR=1.22,95%CI:0.95-1.57)under additive model analyzed by multi-logistic regression model. The means of survival time of AA,AG,GG carriers were 54.19 ± 2.02,44.16 ± 2.59,32.76 ± 5.36 months and there were significant differentia-tion between them in log Rank test(F=11.24,P=0.004). Cox proportional hazard regression model showed that miR-499A > G was significant associated with adverse prognosis of colorectal cancer(HR=1.26,95%CI:1.02-1.57). Conclusion miR-499 A > G has no association with the incidence of colorectal cancer ,but it affects the prognosis of colorectal cancer in Han population.

The protein encoded by the HOXC gene regulates multiple processes during embryonic development,including cell growth,differentiation,apoptosis,migration and angiogenesis.The HOXC gene is also involved in the occurrence and development of various human solid tumors,such as colorectal cancer,gastric cancer,liver cancer,breast cancer,endometrial cancer,etc.In addition,the HOXC gene is closely related to the clinical stage and distant metastasis of the tumor.Thus,the HOXC gene can be used as a biological predictor of tumor metastasis and prognosis.

Objective To explore the changes of depression in patients with lung cancer and their impacts on the survival period,so to provide evidence for psychological treatment of patients with lung cancer.Methods 339 lung cancer patients diagnosed and treated in our hospital and other hospital from 2010 to 2013 were included.The depression status of patients was diagnosed by the Depression Scale of Epidemiological Research Center and followed up every year.To observe the changes of depressive symptoms during the survival period,and to evaluate the impact of depressive symptoms on the survival rate of patients.Results Among 339 participants,133 (39％) had depression symptoms at baseline and an additional 71 (21％) developed new-onset depression symptoms during treatment.At baseline,depression symptoms were associated with increased mortality (hazard ratio [HR],1.19,95％ CI:1.04-1.34).Participants were classified into the following four groups based on longitudinal changes in depression symptoms from baseline to follow-up:never depression symptoms (n =135),new-onset depression symptoms (n =71),depression symptom remission (n =46),and persistent depression symptoms (n =87).HRs were as follows:new-onset depression symptoms,1.36 (95％ CI:1.12-1.61),depression symptom remission,1.11 (95％ CI:0.97-1.25),and persistent depression symptoms,1.33 (95％ CI:1.09-1.57).Conclusions Among patients with lung cancer,longitudinal changes in depression symptoms are associated with differences in mortality.Symptom remission is associated with a similar mortality rate as never having had depression,which is lower than that in persistent and new-onset depression symptoms.